Correlation between virus replication and antibody responses in macaques following infection with pandemic influenza A virus

Journal of Virology

Volumn 90, Issue 2, 2016, Pages 1023-1033

  Koopman, Gerrit ^a   Mooij, Petra ^a   Dekking, Liesbeth ^b   Mortier, Daniëlla ^a   Nieuwenhuis, Ivonne G ^a   van Heteren, Melanie ^a,c   Kuipers, Harmjan ^b   Remarque, Edmond J ^a   Radošević, Katarina ^b,d   Bogers, Willy M J M ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

^c Janssen Research and Development   (Netherlands)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HEMAGGLUTINATION INHIBITION TEST; INFECTIOUS DOSE; INFLUENZA A (H1N1); INFLUENZA A VIRUS; INFLUENZA A VIRUS (A/MEXICO/INDRE4487/2009(H1N1)); MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRACHEA; VIROGENESIS; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; DOSE RESPONSE; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); PHYSIOLOGY; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MACACA FASCICULARIS; MALE; NEUTRALIZATION TESTS; TRACHEA; VIRAL LOAD; VIRUS REPLICATION;

EID: 84954098449     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02757-15     Document Type: Article

References (44)

1. Bouvier NM, Lowen AC. 2010. Animal models for influenza virus pathogenesis and transmission. Viruses 2:1530-1563. http://dx.doi.org/10.3390/v20801530.
2. Davis AS, Taubenberger JK, Bray M. 2015. The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014. Antiviral Res 117:75-98. http://dx.doi.org/10.1016/j.antiviral.2015.02.011.
3. Bodewes R, Rimmelzwaan GF, Osterhaus AD. 2010. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 9:59-72. http://dx.doi.org/10.1586/erv.09.148.
4. Lednicky JA, Croutch CR, Lawrence SJ, Hamilton SB, Daniels DE, Astroff B. 2010. A nonlethal young domesticated ferret (Mustela putorius furo) model for studying pandemic influenza virus A/California/04/2009 (H1N1). Comp Med 60:364-368.
5. Dimmock NJ, Marriott AC. 2006. In vivo antiviral activity: defective interfering virus protects better against virulent influenza A virus than avirulent virus. J Gen Virol 87:1259-1265. http://dx.doi.org/10.1099/vir.0.81678-0.
6. Gustin KM, Belser JA, Wadford DA, Pearce MB, Katz JM, Tumpey TM, Maines TR. 2011. Influenza virus aerosol exposure and analytical system for ferrets. Proc Natl Acad Sci U S A 108:8432-8437. http://dx.doi.org/10.1073/pnas.1100768108.
7. Kiso M, Ozawa M, Le MT, Imai H, Takahashi K, Kakugawa S, Noda T, Horimoto T, Kawaoka Y. 2011. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol 85:4667-4672. http://dx.doi.org/10.1128/JVI.00047-11.
8. MacInnes H, Zhou Y, Gouveia K, Cromwell J, Lowery K, Layton RC, Zubelewicz M, Sampath R, Hofstadler S, Liu Y, Cheng YS, Koster F. 2011. Transmission of aerosolized seasonal H1N1 influenza A to ferrets. PLoS One 6:e24448. http://dx.doi.org/10.1371/journal.pone.0024448.
9. Marriott AC, Dove BK, Whittaker CJ, Bruce C, Ryan KA, Bean TJ, Rayner E, Pearson G, Taylor I, Dowall S, Plank J, Newman E, Barclay WS, Dimmock NJ, Easton AJ, Hallis B, Silman NJ, Carroll MW. 2014. Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir. PLoS One 9:e94090. http://dx.doi.org/10.1371/journal.pone.0094090.
10. McBrayer A, Camp JV, Tapp R, Yamshchikov V, Grimes S, Noah DL, Jonsson CB, Bruder CE. 2010. Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret. Virol J 7:149. http://dx.doi.org/10.1186/1743-422X-7-149.
11. van den Brand JM, Stittelaar KJ, van Amerongen G, Rimmelzwaan GF, Simon J, de Wit E, Munster V, Bestebroer T, Fouchier RA, Kuiken T, Osterhaus AD. 2010. Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis 201:993-999. http://dx.doi.org/10.1086/651132.
12. Fan S, Gao Y, Shinya K, Li CK, Li Y, Shi J, Jiang Y, Suo Y, Tong T, Zhong G, Song J, Zhang Y, Tian G, Guan Y, Xu XN, Bu Z, Kawaoka Y, Chen H. 2009. Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog 5:e1000409. http://dx.doi.org/10.1371/journal.ppat.1000409.
13. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF. 2009. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 199:405-413. http://dx.doi.org/10.1086/595984.
14. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, Draghia-Akli R, Weiner DB. 2009. Electroporation of syntheticDNAantigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 83:4624-4630. http://dx.doi.org/10.1128/JVI.02335-08.
15. Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD. 2001. A single dose of an ISCOM influenza vaccine induces longlasting protective immunity against homologous challenge infection but fails to protect cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 20:158-163. http://dx.doi.org/10.1016/S0264-410X(01)00262-6.
16. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Valleron AJ. 2008. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167:775-785. http://dx.doi.org/10.1093/aje/kwm375.
17. Clements ML, O'Donnell S, Levine MM, Chanock RM, Murphy BR. 1983. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 40:1044-1051.
18. Keitel WA, Couch RB, Cate TR, Six HR, Baxter BD. 1990. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis 161: 22-26. http://dx.doi.org/10.1093/infdis/161.1.22.
19. Murphy BR, Holley HP, Jr, Berquist EJ, Levine MM, Spring SB, Maassab HF, Kendal AP, Chanock RM. 1979. Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. Infect Immun 23:253-259.
20. Murphy BR, Rennels MB, Douglas RG, Jr, Betts RF, Couch RB, Cate TR, Jr, Chanock RM, Kendal AP, Maassab HF, Suwanagool S, Sotman SB, Cisneros LA, Anthony WC, Nalin DR, Levine MM. 1980. Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun 29: 348-355.
21. Sears SD, Clements ML, Betts RF, Maassab HF, Murphy BR, Snyder MH. 1988. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 158:1209-1219. http://dx.doi.org/10.1093/infdis/158.6.1209.
22. Alford RH, Kasel JA, Gerone PJ, Knight V. 1966. Human influenza resulting from aerosol inhalation. Proc Soc Exp Biol Med 122:800-804. http://dx.doi.org/10.3181/00379727-122-31255.
23. Killingley B, Enstone J, Booy R, Hayward A, Oxford J, Ferguson N, Nguyen Van-Tam J, Influenza Transmission Strategy Development Group. 2011. Potential role of human challenge studies for investigation of influenza transmission. Lancet Infect Dis 11:879-886. http://dx.doi.org/10.1016/S1473-3099(11)70142-6.
24. Weinfurter JT, Brunner K, Capuano SV, III, Li C, Broman KW, Kawaoka Y, Friedrich TC. 2011. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 7:e1002381. http://dx.doi.org/10.1371/journal.ppat.1002381.
25. Jegaskanda S, Amarasena TH, Laurie KL, Tan HX, Butler J, Parsons MS, Alcantara S, Petravic J, Davenport MP, Hurt AC, Reading PC, Kent SJ. 2013. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol 87: 13706-13718. http://dx.doi.org/10.1128/JVI.01666-13.
26. Josset L, Engelmann F, Haberthur K, Kelly S, Park B, Kawoaka Y, Garcia-Sastre A, Katze MG, Messaoudi I. 2012. Increased viral loads and exacerbated innate host responses in aged macaques infected with the 2009 pandemic H1N1 influenzaAvirus. J Virol 86:11115-11127. http://dx.doi.org/10.1128/JVI.01571-12.
27. Brining DL, Mattoon JS, Kercher L, LaCasse RA, Safronetz D, Feldmann H, Parnell MJ. 2010. Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis). Comp Med 60:389-395.
28. Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, Brining D, Gardner D, Proll SC, Marzi A, Tsuda Y, Lacasse RA, Kercher L, York A, Korth MJ, Long D, Rosenke R, Shupert WL, Aranda CA, Mattoon JS, Kobasa D, Kobinger G, Li Y, Taubenberger JK, Richt JA, Parnell M, Ebihara H, Kawaoka Y, Katze MG, Feldmann H. 2011. Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous viru lence in macaques. J Virol 85:1214-1223. http://dx.doi.org/10.1128/JVI.01848-10.
29. Mooij P, Koopman G, Mortier D, van Heteren M, Oostermeijer H, Fagrouch Z, de Laat R, Kobinger G, Li Y, Remarque EJ, Kondova I, Verschoor EJ, Bogers WM. 2015. Pandemic swine-origin H1N1 influenza virus replicates to higher levels and induces more fever and acute inflammatory cytokines in cynomolgus versus rhesus monkeys and can replicate in common marmosets. PLoS One 10:e0126132. http://dx.doi.org/10.1371/journal.pone.0126132.
30. Van Wesenbeeck L, Meeuws H, Van Immerseel A, Ispas G, Schmidt K, Houspie L, Van Ranst M, Stuyver L. 2013. Comparison of the FilmArray RP, Verigene RV+ , and Prodesse ProFLU+/FAST+ multiplex platforms for detection of influenza viruses in clinical samples from the 2011-2012 influenza season in Belgium. J Clin Microbiol 51:2977-2985. http://dx.doi.org/10.1128/JCM.00911-13.
31. Mahdi Abdel Hamid M, Remarque EJ, van Duivenvoorde LM, van der Werff N, Walraven V, Faber BW, Kocken CH, Thomas AW. 2011. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS One 6:e20547. http://dx.doi.org/10.1371/journal.pone.0020547.
32. World Health Organization. 2002. WHO manual on animal influenza diagnosis and surveillance. WHO Department of Communicable Disease Surveillance and Response, Geneva, Switzerland.
33. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, Kent SJ. 2013. Crossreactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190:1837-1848. http://dx.doi.org/10.4049/jimmunol.1201574.
34. Chen Z, Liu H, Lu J, Luo L, Li K, Liu Y, Lau EH, Di B, Wang H, Yang Z, Xiao X. 2014. Asymptomatic, mild, and severe influenza A(H7N9) virus infection in humans, Guangzhou, China. Emerg Infect Dis 20:1535-1540. http://dx.doi.org/10.3201/eid2009.140424.
35. Jost S, Altfeld M. 2013. Control of human viral infections by natural killer cells. Annu Rev Immunol 31:163-194. http://dx.doi.org/10.1146/annurev-immunol-032712-100001.
36. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, Garcia-Sastre A, Tolnay AE, Albrecht R, Pyles JA, Olson PH, Aicher LD, Rosenzweig ER, Murali-Krishna K, Clark EA, Kotur MS, Fornek JL, Proll S, Palermo RE, Sabourin CL, Katze MG. 2009. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 106:3455-3460. http://dx.doi.org/10.1073/pnas.0813234106.
37. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. 2013. Antibodydependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 87:5512-5522. http://dx.doi.org/10.1128/JVI.03030-12.
38. European Medicines Agency. 1996. Note for guidance on harmonisation or requirements for influenza vaccines. The European Agency for the Evaluation of Medicinal Products, London, England.
39. CDC. 2006. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMRW Recommend Rep 55(RR10):1-42. http://www.cdc.gov/MMWR/preview/mmwrhtml/rr5510a1.htm.
40. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. 2011. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 30:1081-1085. http://dx.doi.org/10.1097/INF.0b013e3182367662.
41. Lee MS, Mahmood K, Adhikary L, August MJ, Cordova J, Cho I, Kemble G, Reisinger K, Walker RE, Mendelman PM. 2004. Measuring antibody responses to a live attenuated influenza vaccine in children. Pediatr Infect Dis J 23:852-856. http://dx.doi.org/10.1097/01.inf.0000137566.87691.3b.
42. Leroux-Roels I, Leroux-Roels G. 2009. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 8:401-423. http://dx.doi.org/10.1586/erv.09.15.
43. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. 2013. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19:1305-1312. http://dx.doi.org/10.1038/nm.3350.
44. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. 2012. Preexisting influenzaspecific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18:274-280. http://dx.doi.org/10.1038/nm.2612.